Ingenol mebutate as topical treatment for actinic keratosis based on a prospective, non-interventional, multicentre study of real-life clinical practice in Germany: efficacy and quality of life

Diepgen, Thomas L.; Eicke, Christoph; Bastian, Mike

doi:10.1684/ejd.2019.3603

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tool captures the chronic, cyclical nature of AK management and is designed to foster shared decision-making between HCPs and patients at each stage, allowing for the mutual determination of treatment goals and priorities. Treatment option schematics support treatment selection based on rated attributes that matter to patients: good efficacy ( 18 – 20 ), high tolerability ( 18 , 20 , 21 – 23 ), short treatment duration ( 19 , 24 , 25 ), good convenience ( 22 , 23 ) and cosmesis ( 2 ), and field-cancerization management ( 26 ). PDT modalities scored highly across these attributes, aligning with the high patient preference for this treatment method seen in clinical trials ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project

et al. 2023

View full text Add to dashboard Cite

Actinic keratoses are pre-malignant skin lesions that require personalized care, a lack of which may result in poor treatment adherence and suboptimal outcomes. Current guidance on personalizing care is limited, notably in terms of tailoring treatment to individual patient priorities and goals and supporting shared decision-making between healthcare professionals and patients. The aim of the Personalizing Actinic Keratosis Treatment panel, comprised of 12 dermatologists, was to identify current unmet needs in care and, using a modified Delphi approach, develop recommendations to support personalized, long-term management of actinic keratoses lesions. Panellists generated recommendations by voting on consensus statements. Voting was blinded and consensus was defined as ≥ 75% voting ’agree’ or ’strongly agree’. Statements that reached consensus were used to develop a clinical tool, of which, the goal was to improve understanding of disease chronicity, and the need for long-term, repeated treatment cycles. The tool highlights key decision stages across the patient journey and captures the panellist’s ratings of treatment options for attributes prioritized by patients. The expert recommendations and the clinical tool can be used to facilitate patient-centric management of actinic keratoses in daily practice, encompassing patient priorities and goals to set realistic treatment expectations and improve care outcomes.

show abstract